One Beacon Street
Suite 1320
Boston, MA 02108

T 617.720.5090
F 617.720.5092


One Richmond Sq.
Suite 165W
Providence, RI 02906
T 401.454.0400
F 401.454.0404

January 22, 2014

Health Resources and Services Administration’s latest update to 340B and implications


UPDATE: U.S. District Court Ruling Vacates HRSA’s 340B Program Orphan Drug Exclusion Rule Casts Uncertainty on Forthcoming "Mega-Rule"

On January 9, 2014, the Health Resources and Services Administration ("HRSA") issued its latest update to the 340B drug pricing program ("340B"). The program update includes a report on the results from 51 compliance audits of 340B-covered entities, and new information on the much-anticipated 340B regulations expected later this year. It is important for 340B-covered entities to conduct self-audits and to monitor key issues on an ongoing basis.

Audit Results

Final results from audits for 51 340B-covered entities conducted in Fiscal Year 2012, including review of 410 covered entity sites, are now available on the HRSA website. The audit findings vary from minor violations involving incorrect covered entity entries in the 340B database, to findings of statutorily prohibited practices of diversion and duplicate discounts. According to this latest update, 16 covered entities diverted 340B drugs to non-eligible patients, and 18 covered entities obtained duplicate discounts. In addition, 7 of these covered entities were found to have violated both the diversion and duplicate discount prohibitions. In 16 instances, covered entities that violated either the diversion or duplicate discount prohibitions, or both, are being sanctioned by means of repayment to the manufacturer. Some sanctions are still being determined, and 340B-covered entities with reported violations are continuing to work with HRSA to develop corrective action plans to ensure ongoing compliance. HRSA mentions that it will use the results of the audits to develop best practices for 340B program compliance.

Insight on Forthcoming Regulations

HRSA is also drafting much-anticipated 340B program regulations that are designed to cover a number of aspects of the program and to formalize existing program guidance. The program update indicates that HRSA will address the definition of an eligible patient, compliance requirements for contract pharmacies, hospital eligibility criteria, and eligibility of off-site facilities. HRSA expects to publish the proposed regulation for public comment by June 2014.

Conducting Self-Audits

HRSA’s program integrity efforts will continue into this new year and 340B-covered entities should continue to monitor their compliance with program requirements. Self-audits are a great way for 340B-covered entities to prepare for a potential HRSA audit and to gauge their level of compliance. Key issues to be monitored on an ongoing basis and during any self-audits should include a review of relevant policies and procedures, verification of internal controls to prevent diversion and duplicate discounts, Medicaid exclusion file listing, and contract pharmacy arrangement compliance.

About the Author

Diane Moes

Diane Moes is a partner at Barrett & Singal where she provides general business and corporate legal services to healthcare clients including hospitals, physicians and other healthcare providers, faculty practice plans and provider networks.


Health Law



Research Misconduct


This website presents general information about Barrett & Singal and is not intended as legal advice nor should you consider it as such. You should not act upon this information without seeking professional counsel.

Please note that contacting Barrett & Singal by email, telephone or facsimile will not establish an attorney-client relationship, obligate us to act as your attorney or impose an obligation on either the law firm or the receiving lawyer to keep the transmitted information confidential. Completion of Barrett & Singal’s new client intake protocol, including without limitation the firm’s conflicts checking process and an engagement letter, is necessary to establish an attorney-client relationship. Absent a current attorney-client relationship with Barrett & Singal, any information or documents communicated or transmitted by you to Barrett & Singal will not be treated as confidential, secret or protected in any way. If you are not a current client of Barrett & Singal, please do not send any confidential information to us through this web site or otherwise concerning any potential or actual legal matter you have. Before providing any confidential information to us, you must obtain permission to do so from one of the firm’s lawyers. By clicking "Accept," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client.

If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed with the firm attorney before such information is submitted. Thank you for your interest in Barrett & Singal.